Key Highlights

  • INVO Fertility (NASDAQ:IVF) reported a nine-month net loss of about USD 6.8 million for 2026 versus USD 24.4 million a year earlier, with non-cash items of USD 3.0 million against USD 18.7 million.
  • Nine-month Revenue rose roughly 22% to about USD 6.4 million from USD 5.3 million, and third-quarter revenue increased 26% to about USD 2.2 million as new clinics joined.
  • Cash stood at about USD 3.7 million at September 30, 2026, and stockholders' Equity climbed to USD 18.0 million from USD 7.2 million at December 31, 2025.
  • Management still flags substantial doubt about continuing as a going concern, citing dependence on Debt and Equity Financing and an accumulated Deficit of USD 98.2 million.

Clinic Acquisitions Lift Revenue and Cut the Loss

INVO Fertility (NASDAQ:IVF) filed its Quarterly Report on November 16, 2026 for the period ended September 30. The company runs fertility clinics and sells its INVOcell device for assisted reproduction. Nine-month revenue grew by about USD 1.2 million, of which USD 0.7 million came from the Indiana Clinic bought in February and the Alabama Clinic, which became wholly owned in late June, and USD 0.5 million came from organic growth at existing clinics. WFI also benefited from its acceptance into the Progyny network in the first quarter. Cost of services rose about 26% to USD 4.1 million. The Indiana Clinic cost USD 760,000, of which USD 360,000 was cash and USD 400,000 was Series D preferred stock, and the remaining 50% of the Alabama Clinic cost USD 175,001.

Why the Loss Fell So Sharply

Most of the improvement comes from lower non-cash charges. The 2025 period carried a debt extinguishment loss of USD 1.4 million in the third quarter alone, tied to an amended debenture, which did not recur. Third-quarter selling, general and administrative expense held at about USD 2.1 million, while stock-based compensation dropped to USD 0.1 million from USD 0.5 million. The quarter did include a USD 0.6 million loss on derivative Fair Value changes tied to the Any Market Purchase Agreement. Interest expense and financing fees eased to USD 0.2 million from USD 0.3 million. Total liabilities fell USD 5.5 million from December 31, 2025, while total Assets increased USD 5.3 million, which explains the rise in equity.

Funding, Going Concern and Nasdaq Compliance

The company received about USD 7.1 million from Warrant exercises in January 2026 and raised USD 3.5 million under the Any Market Purchase Agreement in August, using proceeds to settle USD 2.2 million and USD 1.3 million of deferred Acquisition payments for WFI. Operating cash outflow was USD 4.7 million, down from USD 7.0 million. A 1-for-5 reverse split took effect on March 27, 2026, and 1,192,860 shares were outstanding on November 16. Nasdaq closed a late-filing matter on June 23, 2026 after the company filed its overdue Annual Report on June 2 and its first-quarter report on June 22. Management plans organic growth and further acquisitions of profitable fertility clinics.

Where Things Stand

INVO Fertility (NASDAQ:IVF) shrank its loss mainly because large non-cash items from 2025 did not repeat, while higher clinic revenue played a supporting role. Operations still burn cash, with USD 4.7 million used over nine months against USD 3.7 million in the bank. The next markers are further clinic acquisitions announced by the company, additional financing under the purchase agreement and whether the going concern language is lifted.